- AU$92.05bn
- AU$107.79bn
- $15.80bn
Brief: CSL Notes Announcement By United States Administration On 2 April
CSL flags global stockout of bleeding disorder gene therapy
Brief: CSL Currently Experiencing Temporary Global Stockout Of HEMGENIX
Brief: Csl Seqirus Signs Agreement With Pan American Health Organization
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Brief: CSL Announces Expansion Of Illinois Plasma Therapy Manufacturing Facility
Australia stocks lose $91 bln in a week as Mideast war weighs after wild earnings season (updated)
Australia stocks lose $93 bln in a week as Mideast war weighs after wild earnings season
Australia's CSL to supply vaccines to Canada in case of flu pandemic; shares jump
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Australian shares climb as NAB sets peak, BlueScope jumps on improved bid
CSL signs licensing deal with Eli Lilly for clazakizumab to explore other potential treatments (updated)
Australian shares climb as NAB sets peak, BlueScope jumps on improved bid
Australia's CSL recovers after signing licensing deal with Eli Lilly
CSL licenses Eli Lilly's clazakizumab to cut cardiac risk in end-stage kidney disease (updated)
CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
Brief: CSL And Lilly Enter Licensing Agreement For Clazakizumab
Brief: CSL Says Neffy, Adrenaline Nasal Spray, Approved To Treat Anaphylaxis In Australia
CSL rout extends into sixth session after CEO departure, weak earnings